Improving quality of life and potentially keeping the cancer under control for a longer period of time are goals of a new clinical trial at the cancer center’s TGen Clinical Research Services, a partnership of Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).
“Many are living with refractory (cancer that has not responded to treatmnent), or advanced, breast cancer that has not responded or continues to grow despite standard treatments,” explains Nurse Practitioner Gayle Jameson, principal investigator.
The pilot study is supported by the Side-Out Foundation, a group founded by volleyball enthusiasts to help wage war on breast cancer.Women or men with advanced breast cancer that has progressed through three prior treatments are eligible for the trial, available in the western U.S. only.The new study, managed by TGen Drug Development (TD2), is open to a total of 25 patients at only two sites, the Virginia G. Piper Cancer Center at Scottsdale Healthcare and Fairfax Northern Virginia Hematology Oncology.
Biopsied tissue will be analyzed for unique characteristics and abnormal genes in cancer cells, which are then targeted for treatment with FDA-approved anticancer medications. “We may discover that a tumor has a gene mutation that responds to a drug not typically used in a ‘one-size-fits-all’ approach,” explains Jameson.
“What we are doing here is precisely matching a treatment to a specific type of cancer cell mutation and abnormal protein signaling pathways that may activate cancer cell growth. The patient would then be treated with one or more medications based on the information provided by the analyses.”
Researchers call the Side-Out study the “next generation of breast cancer treatment,” expanding on what was learned about molecular profiling in an earlier clinical trial at the Virginia G. Piper Cancer Center.
Results of the earlier trial, known as the Bisgrove Study, showed that molecular profiling can identify specific treatments that help keep cancer in check for significantly longer periods, and in some cases even shrinking tumors. Clinical trials at the cancer center are administered by the Scottsdale Healthcare Research Institute.
This is a great step forword in the whole area of personalised medicine which identifies charactertistiscs of disease that are specific to different people.These characteritics can then be targeted more accuratly using the correct medication.Although this is approach is used to some degree in many treatments e.g. identifying hormone receptive breat cancers from those that are not ,this takes that approach to a whole new level.
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments.
Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.
Retrieved March 14, 2010, from http://www.sciencedaily.com /releases/2010/03/100311151722.htm
Other Interesting Articles:
A look at the treatment benefits of differentiating between characteristics of recurrent breat cancer from those of the original cancer :http://www.sciencedaily.com/releases/2009/03/090318211238.htm
Related articles by Zemanta
- TGen team honored for best paper at scientific conference (scienceblog.com)
- Virus eyed as new treatment for prostate cancer (ctv.ca)
- Pfizer says Sutent fails in breast cancer studies (seattletimes.nwsource.com)
- Life Tech to Sequence Breast Cancer Genomes (xconomy.com)
- Gastric Cancer Targeted Therapies – Combination of Targets Prove Effective – UCLA (ducknetweb.blogspot.com)
- Gene test aids breast cancer treatment (telegraph.co.uk)
- Herceptin and Tykerb effective against a subset of gastric cancers (scienceblog.com)